Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Evaluation of soft-tissue lesions with F-18-FDG PET/CT: initial results of a prospective trial

Full text
Author(s):
Leal, Aline L. [1, 2] ; Etchebehere, Mauricio [3] ; Santos, Allan O. [1, 2] ; Kalaf, Gustavo [4] ; Pacheco, Elisa B. [5] ; Amstalden, Eliane M. [6] ; Etchebehere, Elba C. [1, 2]
Total Authors: 7
Affiliation:
[1] Campinas State Univ UNICAMP, Dept Radiol, Div Nucl Med, BR-13083888 Campinas, SP - Brazil
[2] Nucl Med Campinas MN&D, Campinas, SP - Brazil
[3] Campinas State Univ UNICAMP, Dept Orthopaed, BR-13083888 Campinas, SP - Brazil
[4] Campinas Radiol Clin RCC, Campinas, SP - Brazil
[5] Campinas State Univ UNICAMP, Dept Radiol, BR-13083888 Campinas, SP - Brazil
[6] Campinas State Univ UNICAMP, Dept Pathol, BR-13083888 Campinas, SP - Brazil
Total Affiliations: 6
Document type: Journal article
Source: NUCLEAR MEDICINE COMMUNICATIONS; v. 35, n. 3, p. 252-259, MAR 2014.
Web of Science Citations: 5
Abstract

Purpose of the reportAlthough MRI is utilized for planning the resection of soft-tissue tumors, it is not always capable of differentiating benign from malignant lesions. The risk of local recurrence of soft-tissue sarcomas is increased when biopsies are performed before resection and by inadequate resections. PET associated with computed tomography using fluorodeoxyglucose labeled with fluorine-18 (F-18-FDG PET/CT) may help differentiate between benign and malignant tumors, thus avoiding inadequate resections and making prior biopsies unnecessary. The purpose of this study was to evaluate the usefulness of F-18-FDG PET/CT in differentiating benign from malignant solid soft-tissue lesions.Materials and methodsPatients with solid lesions of the limbs or abdominal wall detected by MRI were submitted to F-18-FDG PET/CT. The maximum standardized uptake value (SUVmax) cutoff was determined to differentiate malignant from benign tumors. Regardless of the F-18-FDG PET/CT results all patients underwent biopsy and surgery.ResultsMRI was performed in 54 patients, and 10 patients were excluded because of purely lipomatose or cystic lesions. F-18-FDG PET/CT was performed in the remaining 44 patients. Histopathology revealed 26 (59%) benign and 18 (41%) malignant soft-tissue lesions. A significant difference in SUVmax was observed between benign and malignant soft-tissue lesions. The SUVmax cutoff of 3.0 differentiated malignant from benign lesions with 100% sensitivity, 83.3% specificity, 89.6% accuracy, 78.3% positive predictive value, and 100% negative predictive value.Conclusion(18)F-FDG PET/CT seems to be able to differentiate benign from malignant soft-tissue lesions with good accuracy and very high negative predictive value. Incorporating F-18-FDG PET/CT into the diagnostic algorithm of these patients may prevent inadequate resections and unnecessary biopsies. (C) 2014 Wolters Kluwer Health | Lippincott Williams \& Wilkins. (AU)